Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: a prospective cohort study
Tóm tắt
We investigated the relationship between clinical, laboratory and genetic markers and outcome measures in 159 patients with recent onset of inflammatory arthritis (IA). The majority of patients were managed in community-based rheumatology practice. Median duration of arthritis at baseline was 3 months with median follow-up of 4.0 years (range 0–10). Markers of disease activity and 1987 ACR criteria for rheumatoid arthritis (RA) were estimated every 6 months for the first 2 years and annually thereafter. Presence of shared epitopes (SE) was established by PCR-based method. Main outcome variables were attainment of remission and presence of erosions on X-rays of hands and feet at 3 years. Remission was seen in 34.3% of patients and was independently related to age 60 and older (odds ratio (OR) 3.2; 95% confidence interval (CI), 1.2–8.7) and inversely to the presence of rheumatoid factor (RF) (OR 8.3; 95% CI, 3.2–21.3 for persistent arthritis). Patients with two SE were likely to have persistent arthritis (P=0.006), but this was not significant when corrected for RF. Independent predictors for erosions at 3 years were RF (OR 7.5; 95% CI, 1.9–29.5) and area under the curve for number of swollen joints (OR 1.08; 95% CI, 1.02–1.16). SE status was not predictive of erosions at 3 years (OR 1.6; 95% CI, 0.7–3.7). In univariate analysis, patients possessing DERAA motif on DRB1 were less likely to have erosive disease than without this motif at 4 years (OR 0.21; 95% CI, 0.0–0.9, P=0.037) but this finding was partly explained by adjusting for RF (adjusted OR 0.24; 95% CI 0.04–1.37). In this study of recent onset IA, active disease and RF were associated with poor outcome. Whilst SE did not predict erosive disease, patients with DERAA motif may be protected against erosions whilst the presence of two SE alleles suggests persistence of arthritis.
Tài liệu tham khảo
Van der Heijde DMFM, van Riel PLCM, van Rijswijk MH, van de Putte LBA (1988) Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum 17:284–292
Young A, Corbett M, Winfield J, Jaqueremada D, Williams P, Papasavvas G, Hay F, Roitt I (1988) A prognostic index for erosive changes in hands, feet and cervical spine in early rheumatoid arthritis. Br J Rheumatol 27:94–101
Harrison B, Symmons D (2000) Early inflammatory polyarthritis: result from Norfolk arthritis register with a review of literature. II. Outcome at three years. Rheumatology 39:939–949
Landewe RBM, Boers M, Verhoeven AC, Westhovens R, van de Laar MAFJ, Markusse HM, van Denderen JC, Westedt ML, Peeters AJ, Dijkmans BAC, Jacobs P, Boonen A, van der Heijde DMFM, van der Linden S (2002) Cobra combination therapy in patients with early rheumatoid arthritis. Long-term structural benefits of a brief intervention. Arthritis Rheum 46:347–356
Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, Trang L (1995) Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 22:2208–2213
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Nissilä M, Isomäki H, Kaarela K, Kiviniemi P, Martio J, Sarna S (1983) Prognosis of inflammatory joint diseases. Scan J Rheumatol 12:33–38
Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA (1993) The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. J Rheumatol 20:2005–2009
Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357–365
Harrison BJ, Symmons DPM, Barrett EM, Silman AJ (1998) The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J Rheumatol 25:2324–2330
Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME,Thomson G, Criswell LA (2004) Impact of shared epitope genotype and ethnicity on erosive arthritis. A meta-analysis of 3240 rheumatoid arthritis patients. Arthritis Rheum 50:400–412
Harrison B, Thomson W, Symmons D, Ollier B, Wiles N, Payton T, Barrett E, Silman A (1999) The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. Arthritis Rheum 42:2174–2183
Gough A, Faint J, Salmon M, Hassell A, Wordsworth P, Pilling D, Birley A, Emery P (1994) Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 37:1166–1170
El-Gabalawy HS, Goldbach-Mansky R, Smith D, II, Arayssi T, Bale S, Gulko P, Yarboro C, Wilder RL, Klippel JH, Schumacher HR, Jr (1999) Association of HLA Alleles and the clinical features in the patients with synovitis of recent onset. Arthritis Rheum 42:1696–1705
Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazes JMW, Zwinderman AH, Schreuder GMT, Breedveld FE, de Vries RRP, van der Linden S, Zanelli E, Huizinga TWJ (2002) Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum 46:899–905
De Vries N, Tijssen H, van Riel PLCM, van de Putte LBA (2002) Reshaping the shared epitope hypothesis. HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67–74 of the HLA-DRB1 molecule. Arthritis Rheum 46:921–928
Tuokko J, Nejenstev S, Luukkainen R, Toivanen A, Ilonen J (2001) HLA Haplotype analysis in Finnish patients with rheumatoid arthritis. Arthritis Rheum 44:315–322
Mattey DL, Hassell AB, Plant MJ, Cheung NT, Dawes PT, Jones PW, Thomson W, Poulton KV, Hajeer AH, Ollier WER (1999) The influence of HLA-DRB1 alleles encoding the DERAA amino acid motif on radiological outcome in rheumatoid arthritis. Rheumatology 38:1221–1227
Wagner U, Kaltenhäuser S, Pierer M, Seidel W, Troltzsch M, Häntzschel H, Kalden JR, Wassmuth R (2003) Prospective analysis of the impact of HLA-DR and -DQ on joint destruction in recent-onset rheumatoid arthritis. Rheumatology 42:553–562
Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2002) Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis. Arthritis Rheum 46:906–912
Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW (1968) Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 37:393–406
Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205–1213
Larsen A, Dale K, Eek (1976) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 18:481–491
Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria for rheumatoid arthritis. JAMA 140:659–662
Pincus T, Summey JA, Soraci Jr SA,Wallston KA, Hummon NP (1983) Assessment of patient satisfaction in activities of daily living using modified Stanford Health Assessment Questionnaire. Arthritis Rheum 26:1346–1353
Pinals RS, Masi AT, Larsen RA, and the subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24:1308–1315
StataCorp (1999) Stata Statistical Software: Release 6.0. College Station, TX, US. Stata Corporation
Hulsmans HMJ, Jacobs JWG, van der Heijde DMFM, van Albada-Kuipers GA, Schenk Y, Bijlsma JWJ (2000) The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 43:1927–1940
Weyand CM, Hicok KC, Conn DL, Goronzy JJ (1992) The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Int Med 117:801–806
Machold KP, Stamm TA, Eberl GJM, Nell VKP, Dunky A, Uffmann M, Smolen JS (2002) Very recent onset arthritis– clinical, laboratory and radiological findings during the first year of disease. J Rheumatol 29:2278–2287
Patatantian E, Thompson DF (2002) A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy 22:1157–1162
Woolf AD, Hall ND, Goulding NJ, Kantharia B, Maymo J, Evison G, Maddison PJ (1991) Predictors of the long-term outcome of early synovitis: a 5- year follow-up study. Br J Rheumatol 30:251–254
Eberhardt K, Fex E (1998) Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br J Rheumatol 37:1324–1329
Pease CT, Bhakta BB, Devlin J, Emery P (1999) Does age of onset of rheumatoid arthritis influence phenotype?: a prospective study of outcome and prognostic factors. Rheumatology 38:228–234
Thomson W, Harrison, Ollier B, Wiles N, Payton T, Barrett J, Symmons D, Silman A (1999) Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis. Arthritis Rheum 42:757–762
Fries JF, Wolfe F, Apple R, Erlich H, Bugawan T, Holmes T, Bruce B (2002) HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort. Arthritis Rheum 46:2320–2329
Feigenbaum SL, Masi AT, Kaplan SB (1979) Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adult patients. Am J Med 66:377–384
Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, Meyer O, Sany J, J-P Daures, Dubois A (2001) Prognostic factors for radiographic damage in early rheumatoid arthritis. A multiparameter prospective study. Arthritis Rheum 44:1736–1743
van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, Koster AM, van’t Hof MA, van Rijswijk MH, van de Putte LBA (1992) Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum 35:26–34
van Leeuwen MA, van Rijswijk MH, Sluiter WJ, van Riel PLCM, Kuper IH, van de Putte LBA, Pepys MB, Limburg PC (1997) Individual relationship between progression of radiological damage and acute phase response in early rheumatoid arthritis. Towards development of decision support system. J Rheumatol 24:20–27
Aho K, Heliovaara M, Maatela J, Toumi T, Palosuo T (1999) Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 18:1282–1284
Benoist C, Mathis D (2000) A revival of B cell paradigm for rheumatoid arthritis pathogenesis. Arthritis Res 2:90–94
Rau R, Herborn G, Menninger H, Sangha O (2002) Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology 41:196–204
van der Heide A, Remme CA, Hofman DM, Jacobs JWG, Bijlsma JWJ (1995) Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 38:1466–1474
Van Leeuwen MA, van der Heijde DMFM, van Rijswijk MH, Houtman PM, van Riel PLCM, van de Putte LBA, Limburg PC (1994) Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts and acute phase reactants. J Rheumatol 21:425–429
van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes REM, Huizinga TWJ (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. A prospective cohort study. Arthritis Rheum 50:709–715
Molenaar ETH, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans AC (2004) Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 50:36–42
Constantin A, Lauwers-Cances V, Navaux F, Abbal M, van Meerwijk J, Mazieres B, Cambon-Thomsen A, Cantagrel A (2002) Stromelsyin 1 (Matrix Metalloproteinase 3) and HLA-DRB1 gene polymorphisms. Arthritis Rheum 46:1754–1762
Cook AD, Stockman A, Brand CA, Tait BD, Mackay IR, Muirden KD, Bernard CCA, Rowley MJ (1999) Antibodies to type II collagen and HLA disease susceptibility markers in rheumatoid arthritis. Arthritis Rheum 42:2569–2576